Catalog Products
Now available in our Webshop www.trenzyme.shop
Since 2000, trenzyme has developed a wide range of proteins and cell lines for a variety of research applications, including drug discovery. Our highly skilled and experienced scientific experts provide fast and reliable services to leading global companies, ranging from academia and small biotechs to big pharmaceutical companies.
Facilitating the fast access to high quality proteins and cell lines to support your daily work in research and development, trenzyme provides a continuously growing catalog of off-the-shelf recombinant proteins and cell lines in our webshop www.trenzyme.shop. Reliable results at highest quality standards and with maximum efficiency will save you valuable research time and money and accelerate your innovation.
Catalog Proteins
Viral Proteins and other Target Classes
Catalog Cell Lines
Assay Cell Lines, Production Cell Lines and more
Find recombinant SARS-CoV-2 Proteins in our Webshop
In our webshop you will find ready-to-use SARS-CoV-2 (COVID-19) proteins like SARS-COV-2 Spike S, SARS-CoV-2 Spike S1 RBD, Nucleocapsid (N) protein, Proteinase 3 CL-Mpro, M protein, Envelope (E) protein and other relevant proteins that are associated with Coronavirus infection like hACE2 protein. In addition, we offer a wide range of important SARS-CoV-2 Variants (Spike Mutant Proteins). All proteins can be ordered from stock and have very short delivery times.
Spike S1 (RBD)
Search for various variants of the SARS-CoV-2 (COVID-19) Spike S1 (RBD) protein in our webshop
S trimer
Find different variants of the Spike protein, stabilized trimer, of SARS-CoV-2 (COVID-19) in our webshop
Spike Variants
Variety of SARS-CoV-2 Spike Variants (Indian / U.K. / South Africa / Brazil and other variants) available
human ACE2
Different human ACE-2 protein variants, one of the most important components for Coronavirus research, available in our webshop
Further Corona Proteins
Find further SARS-CoV-2 proteins: SARS-CoV-2 Proteinase 3 CL-Mpro, M protein, E protein and N protein
cGMP cell line for SARS-CoV-2 S1 (RBD)
cGMP-compliant production cell line for the SARS-CoV-2 Spike S1 (RBD) available on request
Relevant Publications
Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples, Journal of Virological Methods, Volume 300 (2022)
Kumari S, Raina A, Chandra D, Gupta N, Dey N, Bhardwaj A K, Anthwal A, Mishra V C, Raina V, Tiwari A K, Setia R, and Bhatia A S
Fluorescence signatures of SARS CoV-2 spike S1 proteins and an human ACE-2: excitation-emission maps and fluorescence lifetimes (2021)
Grzesiak J, Fellner L, Grünewald K, Kölbl C, Walter A, Horlacher R, and Duschek F
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody. Sci Rep 11, 3318 (2021)
Valenzuela Nieto G, Jara R, Watterson D, Modhiran N, Amarilla AA, Himelreichs J, Khromykh AA, Salinas-Rebolledo C, Pinto T, Cheuquemilla Y, Margolles Y, López González del Rey N, Miranda-Chacon Z, Cuevas A, Berking A, Deride C, González-Moraga S, Mancilla H, Maturana D, Langer A, Toledo JP, Müller A, Uberti B, Krall P, Ehrenfeld P, Blesa J, Chana-Cuevas P, Rehren G, Schwefel D, Fernandez LA, and Rojas-Fernandez A
SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study. Viruses 2021, 13, 1143. (2021)
Belogiannis K, Florou VA, Fragkou PC, Ferous S, Chatzis L, Polyzou A, Lagopati N, Touliatou A, Vassilakos D, Kittas C, Tzioufas AG, Tsiodras S, and Gorgoulis V
Ultra-sensitive and fast optical detection of the spike protein of the SARS-COV-2 using AgNPs/SiNWs nanohybrid based sensors (2021)
Daoudi K, Ramachandran K, Alawadhi H, Boukherroub R, Dogheche E, El Khakani MA, and Gaidi M
Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro (2021)
Gauhar A, Privezentzev CV, Demydchuk M, Gerlza T, Rieger J, Kungl AJ, Walsh FJ, Rutkowski JL, and Stocki P
SARS-CoV-2 infects lung epithelial cells and induces senescence and an inflammatory response in patients with severe COVID-19 (2021)
Evangelou K, Veroutis D, Foukas PG, Paschalaki K, Lagopati N, Dimitriou M, Papaspyropoulos A, Hazapis O, Polyzou A, Havaki S, Kotsinas A, Kittas C, Tzioufas AG, de Leval L, Vassilakos D, Tsiodras S, Karakasiliotis I, Barnes PJ, and Gorgoulis VG
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. (2021)
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, and Behrens GMN
Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents (2020)
Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper MM, Behrens GMN, Pöhlmann S, Blasczyk R, Schulz TF, and Förster R
Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Infect Dis Ther 9, 837–849. (2020)
Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, Bosnjak B, Willenzon S, Boeck AL, Tran AT, Thiele T, Graalmann T, Kayser MZ, Zychlinsky Scharff A, Dopfer C, Horke A, Pink I, Witte T, Wetzke M, Ernst D, Jablonka A, and Happle C
Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay (2020)
Emmenegger M, De Cecco E, Lamparter D, Jacquat R, Ebner D, Schneider MM, Condado Morales I, Schneider D, Doğançay B, Guo J, Wiedmer A, Domange J, Imeri M, Moos R, Zografou C, Trevisan C, Gonzalez-Guerra A, Carrella A, Dubach IL, Xu C, Meisl G, Kosmoliaptsis V, Malinauskas T, Burgess-Brown N, Owens R, Mongkolsapaya J, Hatch S, Screaton GR, Schubert K, Huck JD, Liu F, Pojer F, Lau K, Hacker D, Probst-Mueller E, Cervia C, Nilsson J, Boyman O, Saleh L, Spanaus K, von Eckardstein A, Schaer DJ, Ban N, Tsai CJ, Marino J, Schertler GFX, Gottschalk J, Frey BM, Reimann R, Hornemann S, Ring AM, Knowles TPJ, Xenarios I, Stuart DI, and Aguzzi A
Looking for a customized solutions for your recombinant protein production or cell line development project? As research service provider, we offer a wide range of highly customized services for the development of cell lines, stem cells and the recombinant protein production for your project.
Reinhold Horlacher, PhD
Managing Director & CSO
We would be happy to provide you with support on your protein or cell line research project. Let us know your questions and requests, our scientific experts will reply shortly.
Get In Contact With Our Scientific Experts